| BackgroundLung cancer is the leading cause of cancer-related death in most countries, causing over 1 million deaths worldwide each year. Surgical resection is the most effective form of treatment for lung cancer, although at the time of diagnosis, only one-third of patients will have early-stage disease amenable to curative surgery. In addition, a large percentage of patients undergoing surgical resection ultimately die of recurrent disease, suggesting the presence of occult metastatic disease at the time of diagnosis.Mortality from this disease could be reduced greatly through the development of molecular marker that identifies individuals at the earliest stages of lung cancer. Candidate biomarkers should have high sensitivity and specificity and appear early enough in the course of disease for medical intervention to improve prognosis.DNA methylation is an epigenetic modification of DNA. Alternations of the pattern... |